Determining if ingestion of silybum marianum (milk thistle) influences the metabolisation of indinavir in healthy subjects: a randomised controlled phase I study
| ISRCTN | ISRCTN78545137 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN78545137 |
| Protocol serial number | N/A |
| Sponsor | Ontario HIV Treatment Network |
| Funder | Ontario HIV Treatment Network (Canada) |
- Submission date
- 06/11/2002
- Registration date
- 06/11/2002
- Last edited
- 09/10/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Edward Mills
Scientific
Scientific
Director of Research, Canadian College of Naturopathic Medicine
1255 Sheppard Ave East
North York, Ontario
M2K 1E2
Canada
| Phone | +1 416 498 1255 ext 324 |
|---|---|
| emills@ccnm.edu |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Drug interactions |
| Intervention | Milk thistle (silybum marianum) and indinavir. Twenty-four healthy male participants: All individuals will receive a HIV test and Liver Function Tests (LFTs - aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transferase [GGT]) to exclude HIV and liver disease, and also a Complete Blood Count (CBC). Subjects are requested to discontinue all medications, alcohol, caffeine, nicotine and other known CYP 3A4 inducers and inhibitors. Informed consent will be obtained from all participants. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | Milk thistle, indinavir |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 31/12/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Male |
| Target sample size at registration | 24 |
| Key inclusion criteria | 1. Documented Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot results negative for Human Immunodeficiency Virus (HIV) 2. Aged 18 - 35 years 3. Sex male, race Caucasian, and normal findings of laboratory and physical examinations |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/2003 |
| Date of final enrolment | 31/12/2005 |
Locations
Countries of recruitment
- Canada
Study participating centre
Director of Research, Canadian College of Naturopathic Medicine
North York, Ontario
M2K 1E2
Canada
M2K 1E2
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results | 01/03/2005 | Yes | No |